Cyclopharm reshapes board as it accelerates Technegas push in U.S. market

An announcement from Cyclopharm Limited ( (AU:CYC) ) is now available.

Cyclopharm Limited has announced the resignation of Non-Executive Director John Wigglesworth, effective 6 April 2026, as part of a planned board refresh aimed at bolstering U.S. market expertise. Wigglesworth, who joined the board in February 2024 and chaired the Audit and Risk Committee, departs following completion of the year-end financial process, with the company already conducting a formal search for directors better aligned with its next phase of growth in the U.S. healthcare market.

With FDA approval and reimbursement secured for Technegas in the United States and its commercial operations gaining momentum, Cyclopharm is reshaping its board to support accelerated commercialisation of its lung imaging technology. The leadership signalled that further updates to shareholders will follow as the board renewal progresses, underlining the company’s push to strengthen governance and strategic capabilities in line with its expanding U.S. footprint.

The most recent analyst rating on (AU:CYC) stock is a Sell with a A$0.68 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an ASX-listed radiopharmaceutical company that serves the global medical community, focusing on nuclear medicine applications. Its core product is Technegas, a proprietary radiopharmaceutical used for functional lung ventilation imaging, with a growing strategic emphasis on the U.S. healthcare market.

Average Trading Volume: 143,004

Technical Sentiment Signal: Sell

Current Market Cap: A$102.7M

See more data about CYC stock on TipRanks’ Stock Analysis page.